alexa Characterization Of Anti-thrombin-specific RNA Aptamers For Use In Anticoagulant Therapy
ISSN: 2155-9864

Journal of Blood Disorders & Transfusion
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

2nd International Conference on Hematology & Blood Disorders
September 29-October 01, 2014 DoubleTree by Hilton Baltimore-BWI Airport, USA

Yolanda M Fortenberry
ScientificTracks Abstracts: J Blood Disorders Transf
DOI: 10.4172/2155-9864.S1.006
Historically, unfractionated heparin (a complex polysaccharide classified as a glycosaminoglycan) has been used in the treatment and prevention of thromboembolic disorders. However, due to complications associated with heparin (such as bleeding and heparin-induced thrombocytopenia), low molecular weight heparins (LMWHs) have been developed and are being used in place of unfractionated heparin. LMWHs have proven effective as antithrombotic agents; however, the effects of LMWHs cannot be readily reversed, while unfractionated heparin can be reversed by protamine sulfate. The overall goal of this project was to characterize an anti-thrombin (AT)-specific RNA aptamer that will combine the safety and efficacy of LMWH with the reversibility of unfractionated heparin. The author has developed an RNA molecule (aptamer) that binds to AT. Results show that this molecule is able to enhance the inhibition of factor Xa by AT. It was suspected that this aptamer mimics the action of LMWH by binding to the D-helix of AT. Proof of this concept is established by the work of Rusconi et al. who developed an RNA aptamer and RNA aptamer antidote directed against coagulation factor IXa. The factor IXa aptamer completely inhibits the activation of factor X. Its anticoagulant action is controlled by the antidote, which is able to reverse the effects of the factor IXa aptamer within seconds. Preliminary data is present suggesting that an antidote to the AT aptamer has the ability to reverse its activity. If successful, this aptamer/antidote pair will have advantages over LMWHs because not only will it be able to control thrombosis in a fashion similar to LMWHs, but the availability of an antidote will allow for better therapeutic regulation and intervention.
Yolanda M Fortenberry completed her PhD in 2001 from Louisiana State University Health Sciences Center in New Orleans, LA in the Department of Biochemistry and Molecular Biology. She then went on to the University of North Carolina at Chapel Hill where she did her Postdoctoral studies under the mentorship of Dr. Frank Church. She is now an Assistant Professor of Pediatric Hematology and an Adjunct Professor of Biological Chemistry at Johns Hopkins University School of Medicine. Her overall research interest is the development of RNA aptamer molecules of potential therapeutics.
image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version